Related references
Note: Only part of the references are listed.Bladder cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
T. Powles et al.
ANNALS OF ONCOLOGY (2022)
Translesion DNA synthesis mediates acquired resistance to olaparib plus temozolomide in small cell lung cancer
Marcello Stanzione et al.
SCIENCE ADVANCES (2022)
Acquired RAD51C Promoter Methylation Loss Causes PARP Inhibitor Resistance in High-Grade Serous Ovarian Carcinoma
Ksenija Nesic et al.
CANCER RESEARCH (2021)
Overexpressed XRCC2 as an independent risk factor for poor prognosis in glioma patients
Zhendong Liu et al.
MOLECULAR MEDICINE (2021)
Significant value of XRCC2 and XRCC9 expression in the prognosis of human ovarian carcinoma
Yi Liu et al.
JOURNAL OF CANCER (2021)
Increased levels of XPA might be the basis of cisplatin resistance in germ cell tumours
Zuzana Cierna et al.
BMC CANCER (2020)
XPA: DNA Repair Protein of Significant Clinical Importance
Lucia Borszekova Pulzova et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2020)
Inactivation of REV7 enhances chemosensitivity and overcomes acquired chemoresistance in testicular germ cell tumors
Yasutaka Sakurai et al.
CANCER LETTERS (2020)
Enhancing chemotherapy response through augmented synthetic lethality by co-targeting nucleotide excision repair and cell-cycle checkpoints
Yi Wen Kong et al.
NATURE COMMUNICATIONS (2020)
Alterations of DNA damage repair in cancer: from mechanisms to applications
Minlin Jiang et al.
ANNALS OF TRANSLATIONAL MEDICINE (2020)
A PolH Transcript with a Short 3′UTR Enhances PolH Expression and Mediates Cisplatin Resistance
Jin Zhang et al.
CANCER RESEARCH (2019)
Identification of Novel Biomarkers of Homologous Recombination Defect in DNA Repair to Predict Sensitivity of Prostate Cancer Cells to PARP-Inhibitors
Daniela Criscuolo et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2019)
Cancer statistics, 2019
Rebecca L. Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2019)
ERCC1, XPF and XPA-locoregional differences and prognostic value of DNA repair protein expression in patients with head and neck squamous cell carcinoma
Sebastian Prochnow et al.
CLINICAL ORAL INVESTIGATIONS (2019)
Biomarkers for Homologous Recombination Deficiency in Cancer
Michal M. Hoppe et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2018)
Biomarkers for Homologous Recombination Deficiency in Cancer
Michal M. Hoppe et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2018)
DNA repair protein XPA is differentially expressed in colorectal cancer and predicts better prognosis
Xue Feng et al.
CANCER MEDICINE (2018)
Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
Freddie Bray et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2018)
ERCC1 as a prognostic factor for survival in patients with advanced urothelial cancer treated with platinum based chemotherapy: A systematic review and meta-analysis
Yuksel Urun et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2017)
Translesion DNA Synthesis in Cancer: Molecular Mechanisms and Therapeutic Opportunities
Maroof K. Zafar et al.
CHEMICAL RESEARCH IN TOXICOLOGY (2017)
New design of nucleotide excision repair (NER) inhibitors for combination cancer therapy
Francesco Gentile et al.
JOURNAL OF MOLECULAR GRAPHICS & MODELLING (2016)
Neoadjuvant Chemotherapy for Muscle-Invasive Bladder Cancer: A Systematic Review and Two-Step Meta-Analysis
Ming Yin et al.
ONCOLOGIST (2016)
DNA repair targeted therapy: The past or future of cancer treatment?
Navnath S. Gavande et al.
PHARMACOLOGY & THERAPEUTICS (2016)
An Epigenomic Approach to Improving Response to Neoadjuvant Cisplatin Chemotherapy in Bladder Cancer
Evanguelos Xylinas et al.
BIOMOLECULES (2016)
Induction and repair of DNA cross-links induced by sulfur mustard in the A-549 cell line followed by a comet assay
Petr Jost et al.
CHEMICO-BIOLOGICAL INTERACTIONS (2015)
ERCC1 as a Prognostic and Predictive Biomarker for Urothelial Carcinoma of the Bladder following Radical Cystectomy
Tobias Klatte et al.
JOURNAL OF UROLOGY (2015)
Drug-Resistant Urothelial Cancer Cell Lines Display Diverse Sensitivity Profiles to Potential Second-Line Therapeutics
Stefan Vallo et al.
TRANSLATIONAL ONCOLOGY (2015)
122 ERCC1-negative tumors benefit from neoadjuvant cisplatin-based chemotherapy whereas patients with ERCC1-positive tumors do not – results from a cystectomy trial database
T. Hemdan et al.
EUROPEAN UROLOGY SUPPLEMENTS (2014)
Unexpected low-dose toxicity of the universal solvent DMSO
Joana Galvao et al.
FASEB JOURNAL (2014)
Poly(ADP-ribose)-mediated interplay of XPA and PARP1 leads to reciprocal regulation of protein function
Jan M. F. Fischer et al.
FEBS JOURNAL (2014)
Parallel genome-scale loss of function screens in 216 cancer cell lines for the identification of context-specific genetic dependencies
Glenn S. Cowley et al.
SCIENTIFIC DATA (2014)
Epidemiology and Risk Factors of Urothelial Bladder Cancer
Maximilian Burger et al.
EUROPEAN UROLOGY (2013)
Overexpressed DNA Polymerase Iota Regulated by JNK/c-Jun Contributes to Hypermutagenesis in Bladder Cancer
Fang Yuan et al.
PLOS ONE (2013)
Resistance to Bleomycin in Cancer Cell Lines Is Characterized by Prolonged Doubling Time, Reduced DNA Damage and Evasion of G2/M Arrest and Apoptosis
Qi Wang et al.
PLOS ONE (2013)
Expression of DNA Translesion Synthesis Polymerase η in Head and Neck Squamous Cell Cancer Predicts Resistance to Gemcitabine and Cisplatin-Based Chemotherapy
Wendi Zhou et al.
PLOS ONE (2013)
ERCC1 as a biomarker for bladder cancer patients likely to benefit from adjuvant chemotherapy
Jong-Mu Sun et al.
BMC CANCER (2012)
Molecular mechanisms of cisplatin resistance
L. Galluzzi et al.
ONCOGENE (2012)
DNA polymeraseη protein expression predicts treatment response and survival of metastatic gastric adenocarcinoma patients treated with oxaliplatin-based chemotherapy
Kai-yuan Teng et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2010)
Polymerase η mRNA Expression Predicts Survival of Non - Small Cell Lung Cancer Patients Treated with Platinum-Based Chemotherapy
Paolo Ceppi et al.
CLINICAL CANCER RESEARCH (2009)
The fidelity of DNA synthesis by eukaryotic replicative and translesion synthesis polymerases
Scott D. McCulloch et al.
CELL RESEARCH (2008)
Hypersensitivity to cisplatin after hRev3 mRNA knockdown in head and neck squamous cell carcinoma cells
Makoto Adachi et al.
MOLECULAR MEDICINE REPORTS (2008)
Functional characterization of a new p53 mutant generated by homozygous deletion in a neuroblastoma cell line
Yohko Nakamura et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2007)
Outcomes of radical cystectomy for transitional cell carcinoma of the bladder: A contemporary series from the bladder cancer research consortium
Shahrokh F. Shariat et al.
JOURNAL OF UROLOGY (2006)
Impact of renal impairment on eligibility for adjuvant cisplatin-based chemotherapy in patients with urothelial carcinoma of the bladder
Atreya Dash et al.
CANCER (2006)
The RAD51 gene family, genetic instability and cancer
J Thacker
CANCER LETTERS (2005)
DNA double-strand break repair by homologous recombination
A Dudás et al.
MUTATION RESEARCH-REVIEWS IN MUTATION RESEARCH (2004)
The COSMIC (Catalogue of Somatic Mutations in Cancer) database and website
S Bamford et al.
BRITISH JOURNAL OF CANCER (2004)
Molecular views of recombination proteins and their control
SC West
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2003)
Mechanisms of cisplatin resistance in clear cell carcinoma of the ovary
H Itamochi et al.
ONCOLOGY (2002)
Specific DNA adducts induced by some mono-substitued epoxides in vitro and in vivo
M Koskinen et al.
CHEMICO-BIOLOGICAL INTERACTIONS (2000)
Styrene oxide-induced 2′-deoxycytidine adducts, implications for the mutagenicity of styrene oxide
M Koskinen et al.
CHEMICO-BIOLOGICAL INTERACTIONS (2000)
Adenine N3 is a main alkylation site of styrene oxide in double-stranded DNA
M Koskinen et al.
CHEMICO-BIOLOGICAL INTERACTIONS (2000)
Gemcitabine and cisplatin versus methotrexate vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: Results of a large randomized, multinational, multicenter, phase III study
H von der Maase et al.
JOURNAL OF CLINICAL ONCOLOGY (2000)
Share Paper
